Vis enkel innførsel

dc.contributor.authorNieder, Carsten
dc.contributor.authorStanisavljevic, Luka
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorHaukland, Ellinor Christin
dc.date.accessioned2024-09-24T12:37:24Z
dc.date.available2024-09-24T12:37:24Z
dc.date.issued2024-04-15
dc.description.abstractIntroduction: The aim of this study was to evaluate overall survival of men who received systemic therapy with docetaxel for metastatic castrationresistant prostate cancer (MCRPC) in rural Nordland County, Norway. Prognostic factors related to treatment and other variables were evaluated.<p> <p>Material and methods: Overall, 132 pa tients were included in this retrospective study covering the years 2009– 2022. Uni- and multivariate survival analyses were performed. <p>Results: In this elderly cohort (median age 72 years), weekly low-dose docetaxel was the preferred regimen (44%). Seventy-three percent were treated in the first line. Only 11 patients (8%) were pre-exposed to docetaxel in the hormone-sensitive phase. Median survival was 14.3 months. Prognostic factors for longer survival included higher hemoglobin, lower lactate dehydrogenase, administration of docetaxel as firstline MCRPC treatment, and use of fewer prescription drugs for comorbidity. Pre-exposure to docetaxel did not play a major role, p = 0.76. <p>Conclusions: In this rural health care setting, survival after docetaxel was shorter than reported by other groups. Blood test results were confirmed as important prognostic factors. In the present era of evolving treatment sequences, we recommend monitoring of real-world treatment results.en_US
dc.identifier.citationNieder, Stanisavljevic, Dalhaug, Haukland. Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting. Wspólczesna Onkologia. 2024;28(1):31-36en_US
dc.identifier.cristinIDFRIDAID 2273690
dc.identifier.doi10.5114/wo.2024.138842
dc.identifier.issn1428-2526
dc.identifier.issn1897-4309
dc.identifier.urihttps://hdl.handle.net/10037/34845
dc.language.isoengen_US
dc.publisherTermediaen_US
dc.relation.journalWspólczesna Onkologia
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 Termediaen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.titleSurvival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care settingen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)